Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
The medical device registration application of Bonvadis for all indications of wounds has been accepted by Health Canada.
2025
2024
2023
2022
2021
2020
2019
2018
2017
Home
/
Latest News
/
2022
2022
Date
Title
2022-12-23
Oneness Biotech to Present at the 41st Annual J.P. Morgan Healthcare Conference
>
2022-12-21
Oneness announces the information about the investor’s conference of 2022 Q4.
>
2022-12-20
Oneness and Microbio (Shanghai) signed an agreement with Cho Pharma to jointly develop glycosylation-based nucleic acid delivery technology.
>
2022-12-20
Oneness Biotech Co., Ltd. receives a Malaysian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).
>
2022-12-06
Oneness has been invited for a poster presentation with on-site Q&A for the Phase 3 MRCT post-hoc analysis of the DFU new drug, Fespixon at IDF Congress 2022.
>
2022-12-02
The post-market hard-to-heal cases treated by the DFU new drug, Fespixon have been accepted for an oral presentation at 2022 CDS
>
2022-11-29
The trading of Oneness securities in centralized securities exchange market follows Announcement or Notice of Attention to Trading Information
>
2022-11-09
The Board of Directors of Oneness has approved a donation to Teh-Tzer Study Group for Human Medical Research Foundation.
>
2022-11-09
The Company’s 2022Q3 consolidated financial statements have been approved by the Board of Directors
>
2022-11-09
Announce the change of the corporate governance officer.
>
2022-10-27
Oneness Biotech Co., Ltd. receives Israeli, Mexican and Hong Kong patents on the producing recombinant glycoproteins with modified glycosylation.
>
2022-09-29
News-The first in the world! New drug for diabetic foot ulcer: research and development code “ON101”
>
2022-09-28
Fespixon’s clinical meaningfulness as a macrophage- regulation new drug compared with other DFU treatments has been reviewed and published in Pharmaceutics.
>
2022-09-23
Oneness announces the information about the investor’s conference of 2022 Q3.
>
2022-09-23
SNS812, a broad-spectrum siRNA co-developed by Oneness and Microbio (Shanghai) to treat SARS-CoV-2 infection, was greenlighted by FDA to proceed with a Ph1 study
>
1
2
3
4
Next »
